LQDALiquidia Corporation
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+12% of shares).
Rangebound, no clear trend. Oversold (RSI 20). Price is −46% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How LQDA is trading
Liquidia Corporation is +15% over the past year while the S&P 500 is +18%: 3.1 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −46%
vs 200-day average · a clear downtrend
- RSI (14)
- 20
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 70%
Below its 52-week high
Details›
- Last close2026-10-09
- $27.39
- 1 monthS&P 500 +2.7%
- −60%
- 1 yearS&P 500 +18%
- +15%
- 5 yearsS&P 500 +88%
- +949%
- vs 50-day average$66.40
- −59%
- 52-week high
- $91.06
- 52-week low
- $21.80
- Annualised volatility
- 75%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$146M
| Year | Return |
|---|---|
| 2026 (year to date) | −21% |
| 2025 | +193% |
| 2024 | −2.2% |
| 2023 | +89% |
| 2022 | +31% |
| 2021 | +65% |
| 2020 | −31% |
| 2019 | −80% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 8 | 6 of 8 | +8.1% |
| Feb | 8 | 6 of 8 | +4.3% |
| Mar | 8 | 4 of 8 | −1.2% |
| Apr | 8 | 3 of 8 | −5.8% |
| May | 8 | 7 of 8 | +20% |
| Jun | 8 | 2 of 8 | −3.5% |
| Jul | 8 | 3 of 8 | +1.3% |
| Aug | 9 | 4 of 9 | +1.9% |
| Sep | 9 | 3 of 9 | −1.8% |
| Oct | 9 | 5 of 9 | +1.3% |
| Nov | 8 | 6 of 8 | +7.5% |
| Dec | 8 | 6 of 8 | +15% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #30 of 41 by RyuScore